Skip to content
Inciteful Med

Treatments, Procedures, and Liver Transplant

Last updated:

There is no FDA-approved medication to cure Primary Sclerosing Cholangitis (PSC), but symptoms and complications can be effectively managed. Standard treatments include moderate-dose UDCA, ERCP balloon dilation for severe bile duct blockages, and liver transplantation for end-stage disease.

Key Takeaways

  • • There is currently no FDA-approved medical therapy that can completely stop or reverse Primary Sclerosing Cholangitis.
  • • Ursodeoxycholic acid (UDCA) is often used to improve liver enzymes, but high doses are unsafe and increase the risk of serious complications.
  • • Severe bile duct blockages (dominant strictures) are typically treated using ERCP with balloon dilation rather than permanent stents.
  • • Liver transplantation is the only curative and life-extending treatment for end-stage PSC, offering excellent long-term survival rates.
  • • While PSC can recur after a liver transplant, many patients live for decades managing their condition before a transplant is ever needed.

Managing Primary Sclerosing Cholangitis (PSC) can be frustrating because there is currently no medical therapy—no pill or injection—that is FDA-approved to stop or reverse the disease [1][2]. Because PSC is rare and progresses slowly, it has been difficult for researchers to prove that any single drug can prevent the need for a liver transplant [3][4]. However, there are several ways doctors manage the condition to improve your quality of life and handle complications.

The UDCA Controversy

Ursodeoxycholic acid (UDCA), a naturally occurring bile acid, is the most common medication prescribed for PSC, but its use is controversial among specialists [5][6].

  • The Benefit: In standard weight-based dosing (typically 13–20 mg/kg/day), UDCA often improves liver enzymes, specifically Alkaline Phosphatase (ALP) [6][7].
  • The Controversy: Large studies have not yet proven that UDCA helps patients live longer or avoid a transplant [5][6]. Even if your blood tests look better, the underlying scarring may still progress [8].
  • The Risk: A major clinical trial found that high-dose UDCA (28–30 mg/kg/day) actually increased the risk of serious liver complications and was stopped early [9]. If you are prescribed UDCA, it is vital to ensure your dose is within the safe, moderate range.

Managing Blockages with ERCP

When PSC causes a severe narrowing in a major bile duct, it is called a dominant stricture [10]. These blockages can lead to itching, jaundice, and dangerous infections called bacterial cholangitis [11].

To open these blockages, doctors use Endoscopic Retrograde Cholangiopancreatography (ERCP). During this procedure:

  • Balloon Dilation: A small balloon is inflated inside the narrowed duct to stretch it open [12]. This is generally preferred over permanent stents because it has a significantly lower risk of causing serious infections [13][14].
  • Monitoring: ERCP also allows doctors to take samples (brushings) of the duct to check for precancerous cells, which is a critical part of long-term safety [15].

Liver Transplantation: The Path to a Cure

For patients with end-stage liver disease or life-threatening recurrent infections, liver transplantation is the only life-extending or curative treatment option [16][17].

  • Excellent Outcomes: Survival rates after a transplant for PSC are generally excellent—one study showed a 91% survival rate after 5 years for certain patient groups [18].
  • MELD Exceptions: The standard “MELD” score determines your place on the transplant list based on lab values. Because this score may not fully reflect how sick a PSC patient feels (especially if they have severe, recurring infections), national transplant networks (like UNOS in the US) grant “exception points” based on standardized criteria. Your transplant center applies for these points on your behalf [19][20].
  • Recurrence: It is important to know that PSC can return in the new liver (recurrent PSC) in about 20% to 25% of patients [21][22]. This is often managed with the same monitoring and treatments used for the original liver.

While the word “transplant” can be scary, many patients live for decades with PSC before ever needing one, and many never require one at all. Regular monitoring and managing symptoms are the keys to a long, high-quality life with this condition. You can read more about how doctors track your risk in the Understanding Prognosis and Risk Scores page.

Frequently Asked Questions

Is there a cure for Primary Sclerosing Cholangitis?
Currently, there is no FDA-approved pill or injection that can stop or reverse PSC. However, liver transplantation serves as a highly effective, life-extending option for patients whose disease progresses to end-stage liver failure.
What is UDCA and is it safe to take for PSC?
Ursodeoxycholic acid (UDCA) is a bile acid medication commonly prescribed to improve liver enzymes. While moderate, weight-based doses can be beneficial, high doses can increase the risk of serious liver complications. Always discuss the exact dosage with your hepatologist.
How do doctors treat severe bile duct blockages in PSC?
Doctors typically use a procedure called ERCP with balloon dilation to stretch open severe narrowings, known as dominant strictures. This method is generally preferred over using permanent stents because it carries a significantly lower risk of causing serious infections.
Can PSC come back after I have a liver transplant?
Yes, PSC can return in the new liver in about 20% to 25% of transplant recipients. If recurrence happens, doctors manage it using the same routine monitoring and treatment strategies used for your original liver.

Questions for Your Doctor

  • • If you are prescribing UDCA, what is the specific dosage (mg/kg) and is it within the safe 'moderate' range?
  • • Since my ALP levels are still high, what other risk scores (like UK-PSC or PREsTo) can we use to better predict my long-term outlook?
  • • My imaging shows a narrowing in the bile duct—is this a 'dominant stricture' that requires balloon dilation via ERCP?
  • • What are the risks of post-ERCP pancreatitis for someone with my specific anatomy, and how will we prevent it?
  • • At what point in my disease progression should I be referred to a transplant center for an initial evaluation?
  • • If I need a transplant, what is the risk of PSC recurring in the new liver, and how will we monitor for that?

Questions for You

  • • How many episodes of 'cholangitis' (fever, chills, and jaundice) have I experienced in the last six months?
  • • Have I been consistent with my blood work to monitor if my liver enzymes (especially Alkaline Phosphatase) are responding to treatment?
  • • How do I feel about the possibility of an invasive procedure like ERCP versus continuing with monitoring and medication?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Primary sclerosing cholangitis: A review and update.

    Tabibian JH, Bowlus CL

    Liver research (Beijing, China) 2017; (1(4)):221-230 doi:10.1016/j.livres.2017.12.002.

    PMID: 29977644
  2. 2

    A review of the medical treatment of primary sclerosing cholangitis in the 21st century.

    Goode EC, Rushbrook SM

    Therapeutic advances in chronic disease 2016; (7(1)):68-85 doi:10.1177/2040622315605821.

    PMID: 26770670
  3. 3

    Primary sclerosing cholangitis: what is new in the therapeutic landscape.

    Curto A, Cristoferi L, Carbone M, et al.

    Current opinion in immunology 2025; (96()):102613 doi:10.1016/j.coi.2025.102613.

    PMID: 40683116
  4. 4

    New therapies target the toxic consequences of cholestatic liver disease.

    Jansen PLM

    Expert review of gastroenterology & hepatology 2018; (12(3)):277-285 doi:10.1080/17474124.2018.1424538.

    PMID: 29310470
  5. 5

    Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.

    Saffioti F, Gurusamy KS, Hawkins N, et al.

    The Cochrane database of systematic reviews 2017; (3()):CD011343 doi:10.1002/14651858.CD011343.pub2.

    PMID: 28417463
  6. 6

    Berberine Ursodeoxycholate for the Treatment of Primary Sclerosing Cholangitis: The Search for the Elusive Pharmacologic Holy Grail Will Need to Continue.

    Yoshida EM

    The American journal of gastroenterology 2022; (117(11)):1762-1763 doi:10.14309/ajg.0000000000001999.

    PMID: 36327435
  7. 7

    Treatment of Primary Sclerosing Cholangitis Including Transplantation.

    Wheless WH, Russo MW

    Clinics in liver disease 2024; (28(1)):171-182 doi:10.1016/j.cld.2023.07.008.

    PMID: 37945158
  8. 8

    Gamma Glutamyltransferase Reduction Is Associated With Favorable Outcomes in Pediatric Primary Sclerosing Cholangitis.

    Deneau MR, Mack C, Abdou R, et al.

    Hepatology communications 2018; (2(11)):1369-1378 doi:10.1002/hep4.1251.

    PMID: 30411083
  9. 9

    Serum miRNA profiles are altered in patients with primary sclerosing cholangitis receiving high-dose ursodeoxycholic acid.

    Hochberg JT, Sohal A, Handa P, et al.

    JHEP reports : innovation in hepatology 2023; (5(6)):100729 doi:10.1016/j.jhepr.2023.100729.

    PMID: 37179785
  10. 10

    Endoscopic Management of Primary Sclerosing Cholangitis.

    Barkin JA, Levy C, Souto EO

    Annals of hepatology 2017; (16(6)):842-850 doi:10.5604/01.3001.0010.5274.

    PMID: 29055922
  11. 11

    Chronic cholestatic liver diseases - Primary biliary cholangitis and Primary sclerosing cholangitis.

    Fejfar T, Vaňásek T, Hůlek P

    Vnitrni lekarstvi 2020; (66(5)):287-300.

    PMID: 32942866
  12. 12

    No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis.

    Ponsioen CY, Arnelo U, Bergquist A, et al.

    Gastroenterology 2018; (155(3)):752-759.e5 doi:10.1053/j.gastro.2018.05.034.

    PMID: 29803836
  13. 13

    Update in the Care and Management of Patients with Primary Sclerosing Cholangitis.

    Sedki M, Levy C

    Current gastroenterology reports 2018; (20(7)):29 doi:10.1007/s11894-018-0635-8.

    PMID: 29886518
  14. 14

    Endoscopic management of primary sclerosing cholangitis.

    Mizuno S, Uchida Y, Ando S, et al.

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society 2025; (37(7)):723-732 doi:10.1111/den.15010.

    PMID: 40049717
  15. 15

    Non-invasive diagnosis and follow-up of primary sclerosing cholangitis.

    Chazouillères O, Potier P, Bouzbib C, et al.

    Clinics and research in hepatology and gastroenterology 2022; (46(1)):101775 doi:10.1016/j.clinre.2021.101775.

    PMID: 34332142
  16. 16

    Primary sclerosing cholangitis.

    Rabiee A, Silveira MG

    Translational gastroenterology and hepatology 2021; (6()):29 doi:10.21037/tgh-20-266.

    PMID: 33824933
  17. 17

    Novel preclinical developments of the primary sclerosing cholangitis treatment landscape.

    Sohal A, Kowdley KV

    Expert opinion on investigational drugs 2024; (33(4)):335-345 doi:10.1080/13543784.2024.2330738.

    PMID: 38480008
  18. 18

    Donor-Recipient Race Mismatch Is Associated with Lower Survival After Liver Transplantation for Primary Sclerosing Cholangitis.

    Russo MW, Wheless W, Cherikh WS, et al.

    Journal of clinical medicine 2025; (14(15)) doi:10.3390/jcm14155441.

    PMID: 40807064
  19. 19

    Liver transplantation for cholestatic liver diseases: Timing and disease recurrence.

    Cançado GGL, Deeb M, Gulamhusein AF

    Hepatology (Baltimore, Md.) 2025; (82(4)):1016-1035 doi:10.1097/HEP.0000000000001268.

    PMID: 39960305
  20. 20

    Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis.

    Onofrio F, Zheng K, Xu C, et al.

    Hepatology communications 2023; (7(8)) doi:10.1097/HC9.0000000000000219.

    PMID: 37534935
  21. 21

    Timing, Management, and Outcomes of Liver Transplantation in Primary Sclerosing Cholangitis.

    Martin EF, Levy C

    Seminars in liver disease 2017; (37(4)):305-313 doi:10.1055/s-0037-1608655.

    PMID: 29272893
  22. 22

    Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.

    Steenstraten IC, Sebib Korkmaz K, Trivedi PJ, et al.

    Alimentary pharmacology & therapeutics 2019; (49(6)):636-643 doi:10.1111/apt.15148.

    PMID: 30740723

This page provides informational content about Primary Sclerosing Cholangitis treatments and procedures. Always consult your hepatologist or transplant team for medical advice tailored to your specific condition.

Stay up to date

Get notified when new research about Primary sclerosing cholangitis is published.

No spam. Unsubscribe anytime.